MicroRNAs in diabetic kidney disease

International Journal of Endocrinology

Volumn 2014, Issue , 2014, Pages

  Li, Rong ^a,b   Chung, Arthur C K ^a   Yu, Xueqing ^c   Lan, Hui Y ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b First People's Hospital of Yunnan Province   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84893847288     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2014/593956     Document Type: Review

References (111)

1. Shaw J. E., Sicree R. A., Zimmet P. Z., Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Research and Clinical Practice 2010 87 1 4 14 2-s2.0-73749083481 10.1016/j.diabres.2009.10.007
2. Jones C. A., Krolewski A. S., Rogus J., Xue J. L., Collins A., Warram J. H., Epidemic of end-stage renal disease in people with diabetes in the United States population: do we know the cause? Kidney International 2005 67 5 1684 1691 2-s2.0-17744374798 10.1111/j.1523-1755.2005.00265.x (Pubitemid 40577702)
3. Fioretto P., Caramori M. L., Mauer M., The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007. Diabetologia 2008 51 8 1347 1355 2-s2.0-48149097372 10.1007/s00125-008-1051-7
4. Hasslacher C., Ritz E., Wahl P., Michael C., Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrology Dialysis Transplantation 1989 4 10 859 863 2-s2.0-0024807056 (Pubitemid 20031053)
5. Miner J. H., Renal basement membrane components. Kidney International 1999 56 6 2016 2024 2-s2.0-0033460287 10.1046/j.1523-1755.1999.00785.x (Pubitemid 30004730)
6. Kanwar Y. S., Sun L., Xie P., Liu F.-Y., Chen S., A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annual Review of Pathology 2011 6 395 423 2-s2.0-79751477368 10.1146/annurev.pathol.4.110807.092150
7. Lewis E. J., Hunsicker L. G., Bain R. P., Rohde R. D., The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The New England Journal of Medicine 1993 329 20 1456 1462 2-s2.0-0027517659 10.1056/NEJM199311113292004 (Pubitemid 23335891)
8. Brenner B. M., Cooper M. E., De Zeeuw D., Keane W. F., Mitch W. E., Parving H.-H., Remuzzi G., Snapinn S. M., Zhang Z., Shahinfar S., Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England Journal of Medicine 2001 345 12 861 869 2-s2.0-0035922441 10.1056/NEJMoa011161
9. Lewis E. J., Hunsicker L. G., Clarke W. R., Berl T., Pohl M. A., Lewis J. B., Ritz E., Atkins R. C., Rohde R., Raz I., Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. The New England Journal of Medicine 2001 345 12 851 860 2-s2.0-0035922447 10.1056/NEJMoa011303
10. The Diabetes Control, Complications Trial, Epidemiology of Diabetes Interventions, Complications Research Group, Retinopathy and nephropathy in patients with type 1 diabetes four years after a Trial of Intensive Therapy. The New England Journal of Medicine 342 381 389. Erratum in The New England Journal of Medicine, vol. 342, no. 18, article 1376, 2000 10.1056/NEJM200002103420603
11. Ziyadeh F. N., Sharma K., Overview: combating diabetic nephropathy. Journal of the American Society of Nephrology 2003 14 5 1355 1357 2-s2.0-0037407935 10.1097/01.ASN.0000065608.37756.58 (Pubitemid 36514676)
12. Ritz E., Orth S. R., Nephropathy in patients with type 2 diabetes mellitus. The New England Journal of Medicine 1999 341 15 1127 1133 2-s2.0-0033533807 10.1056/NEJM199910073411506 (Pubitemid 29466226)
13. Blumenthal S. S., Evolution of treatment for diabetic nephropathy: historical progression from RAAS inhibition and onward. Postgraduate Medicine 2011 123 6 166 179 2-s2.0-82155192728 10.3810/pgm.2011.11.2506
14. Lee R. C., Feinbaum R. L., Ambros V., The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993 75 5 843 854 2-s2.0-0027751663 10.1016/0092-8674(93)90529-Y (Pubitemid 24014542)
15. Wightman B., Ha I., Ruvkun G., Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993 75 5 855 862 2-s2.0-0027730383 10.1016/0092-8674(93)90530-4 (Pubitemid 24014543)
16. Taganov K. D., Boldin M. P., Chang K.-J., Baltimore D., NF- B-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proceedings of the National Academy of Sciences of the United States of America 2006 103 33 12481 12486 2-s2.0-33747608638 10.1073/pnas.0605298103 (Pubitemid 44267285)
17. Esquela-Kerscher A., Slack F. J., Oncomirs-microRNAs with a role in cancer. Nature Reviews Cancer 2006 6 4 259 269 2-s2.0-33645294070 10.1038/nrc1840
18. Poy M. N., Eliasson L., Krutzfeldt J., Kuwajima S., Ma X., MacDonald P. E., Pfeffer S., Tuschl T., Rajewsky N., Rorsman P., Stoffel M., A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004 432 7014 226 230 2-s2.0-9144270691 10.1038/nature03076 (Pubitemid 39545853)
19. Bushati N., Cohen S. M., MicroRNA functions. Annual Review of Cell and Developmental Biology 2007 23 175 205 2-s2.0-34547960488 10.1146/annurev. cellbio.23.090506.123406
20. Janssen H. L. A., Reesink H. W., Lawitz E. J., Zeuzem S., Rodriguez-Torres M., Patel K., van der Meer A. J., Patick A. K., Chen A., Zhou Y., Persson R., King B. D., Kauppinen S., Levin A. A., Hodges M. R., Treatment of HCV infection by targeting microRNA. The New England Journal of Medicine 2013 368 1685 1694 10.1056/NEJMoa1209026
21. Chang T.-C., Mendell J. T., MicroRNAs in vertebrate physiology and human disease. Annual Review of Genomics and Human Genetics 2007 8 215 239 2-s2.0-35348821616 10.1146/annurev.genom.8.080706.092351
22. Chen C.-Z., MicroRNAs as oncogenes and tumor suppressors. The New England Journal of Medicine 2005 353 17 1768 1771 2-s2.0-27244432205 10.1056/NEJMp058190 (Pubitemid 41549888)
23. Hennessy E., O'Driscoll L., Molecular medicine of microRNAs: structure, function and implications for diabetes. Expert Reviews in Molecular Medicine 2008 10, article e24 10.1017/S1462399408000781
24. Saal S., Harvey S. J., MicroRNAs and the kidney: coming of age. Current Opinion in Nephrology and Hypertension 2009 18 4 317 323 2-s2.0-67849099709 10.1097/MNH.0b013e32832c9da2
25. Kato M., Natarajan R., MicroRNa cascade in diabetic kidney disease: big impact initiated by a small RNA. Cell Cycle 2009 8 22 3613 3614 2-s2.0-70450039323 10.4161/cc.8.22.9816
26. Kato M., Arce L., Natarajan R., MicroRNAs and their role in progressive kidney diseases. Clinical Journal of the American Society of Nephrology 2009 4 7 1255 1266 2-s2.0-70349337337 10.2215/CJN.00520109
27. Kaucsár T., Rácz Z., Hamar P., Post-transcriptional gene-expression regulation by micro RNA (miRNA) network in renal disease. Advanced Drug Delivery Reviews 2010 62 14 1390 1401 2-s2.0-78649448548 10.1016/j.addr.2010.10.003
28. Li J. Y. Z., Yong T. Y., Michael M. Z., Gleadle J. M., Review: the role of microRNAs in kidney disease. Nephrology 2010 15 6 599 608 2-s2.0-77956195166 10.1111/j.1440-1797.2010.01363.x
29. Akkina S., Becker B. N., MicroRNAs in kidney function and disease. Translational Research 2011 157 4 236 240 2-s2.0-79952787452 10.1016/j.trsl.2011.01.011
30. Lorenzen J. M., Haller H., Thum T., MicroRNAs as mediators and therapeutic targets in chronic kidney disease. Nature Reviews Nephrology 2011 7 5 286 294 2-s2.0-79955593914 10.1038/nrneph.2011.26
31. Bhatt K., Mi Q.-S., Dong Z., MicroRNAs in kidneys: biogenesis, regulation, and pathophysiological roles. The American Journal of Physiology: Renal Physiology 2011 300 3 F602 F610 2-s2.0-79954468469 10.1152/ajprenal.00727. 2010
32. Ho J., Kreidberg J. A., The long and short of microRNAs in the kidney. Journal of the American Society of Nephrology 2012 23 3 400 404 2-s2.0-84857975839 10.1681/ASN.2011080797
33. Kantharidis P., Wang B., Carew R. M., Lan H. Y., Diabetes complications: the microRNA perspective. Diabetes 2011 60 7 1832 1837 2-s2.0-80052102044 10.2337/db11-0082
34. Kato M., Park J. T., Natarajan R., MicroRNAs and the glomerulus. Experimental Cell Research 2012 318 9 993 1000 2-s2.0-84859851733 10.1016/j.yexcr.2012.02.034
35. Chandrasekaran K., Karolina D. S., Sepramaniam S., Armugam A., Wintour E. M., Bertram J. F., Jeyaseelan K., Role of microRNAs in kidney homeostasis and disease. Kidney International 2012 81 7 617 627 2-s2.0-84858328459 10.1038/ki.2011.448
36. Pandey A. K., Agarwal P., Kaur K., Datta M., MicroRNAs in diabetes: tiny players in big disease. Cellular Physiology and Biochemistry 2009 23 4-6 221 232 2-s2.0-66749146650 10.1159/000218169
37. Ma L., Qu L., The function of microRNAs in renal development and pathophysiology. Journal of Genetics and Genomics 2013 40 4 143 152 10.1016/j.jgg.2013.03.002
38. Ho J., Kreidberg J. A., MicroRNAs in renal development. Pediatric Nephrology 2013 28 2 219 225 10.1007/s00467-012-2204-y
39. Chung A. C., Yu X., Lan H. Y., MicroRNA and nephropathy: emerging concepts. International Journal of Nephrology and Renovascular Disease 2013 6 169 179 10.2147/IJNRD.S37885
40. Chendrimada T. P., Gregory R. I., Kumaraswamy E., Norman J., Cooch N., Nishikura K., Shiekhattar R., TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 2005 436 7051 740 744 2-s2.0-23644433363 10.1038/nature03868 (Pubitemid 41117280)
41. Gregory R. I., Chendrimada T. P., Cooch N., Shiekhattar R., Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 2005 123 4 631 640 2-s2.0-27744537851 10.1016/j.cell.2005.10.022 (Pubitemid 41608466)
42. MacRae I. J., Ma E., Zhou M., Robinson C. V., Doudna J. A., In vitro reconstitution of the human RISC-loading complex. Proceedings of the National Academy of Sciences of the United States of America 2008 105 2 512 517 2-s2.0-38649111931 10.1073/pnas.0710869105 (Pubitemid 351171739)
43. Robb G. B., Rana T. M., RNA helicase A interacts with RISC in human cells and functions in RISC loading. Molecular Cell 2007 26 4 523 537 2-s2.0-34248576287 10.1016/j.molcel.2007.04.016 (Pubitemid 46765183)
44. Vallon V., Komers R., Pathophysiology of the diabetic kidney. Comprehensive Physiology 2011 1 1175 1232 10.1002/cphy.c100049
45. Harvey S. J., Jarad G., Cunningham J., Goldberg S., Schermer B., Harfe B. D., McManus M. T., Benzing T., Miner J. H., Podocyte-specific deletion of dicer alters cytoskeletal dynamics and causes glomerular disease. Journal of the American Society of Nephrology 2008 19 11 2150 2158 2-s2.0-55749103053 10.1681/ASN.2008020233
46. Ho J., Kar H. N., Rosen S., Dostal A., Gregory R. I., Kreidberg J. A., Podocyte-specific loss of functional microRNAs leads to rapid glomerular and tubular injury. Journal of the American Society of Nephrology 2008 19 11 2069 2075 2-s2.0-55749104549 10.1681/ASN.2008020162
47. Shi S., Yu L., Chiu C., Sun Y., Chen J., Khitrov G., Merkenschlager M., Holzman L. B., Zhang W., Mundel P., Bottinger E. P., Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis. Journal of the American Society of Nephrology 2008 19 11 2159 2169 2-s2.0-55749112141 10.1681/ASN.2008030312
48. Kato M., Zhang J., Wang M., Lanting L., Yuan H., Rossi J. J., Natarajan R., MicroRNA-192 in diabetic kidney glomeruli and its function in TGF- β -induced collagen expression via inhibition of E-box repressors. Proceedings of the National Academy of Sciences of the United States of America 2007 104 9 3432 3437 2-s2.0-33847682663 10.1073/pnas.0611192104 (Pubitemid 46364176)
49. Long J., Wang Y., Wang W., Chang B. H. J., Danesh F. R., MicroRNA-29c is a signature MicroRNA under high glucose conditions that targets sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy. The Journal of Biological Chemistry 2011 286 13 11837 11848 2-s2.0-79953215711 10.1074/jbc.M110.194969
50. Mu J., Pang Q., Guo Y.-H., Chen J.-G., Zeng W., Huang Y.-J., Zhang J., Feng B., Functional implications of MicroRNA-215 in TGF- β 1-induced phenotypic transition of mesangial cells by targeting CTNNBIP1. PLoS ONE 2013 8 e58622
51. Karolina D. S., Armugam A., Tavintharan S., Wong M. T. K., Lim S. C., Sum C. F., Jeyaseelan K., MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. PLoS ONE 2011 6 8 2-s2.0-79960932477 10.1371/journal.pone.0022839 e22839
52. Kato M., Arce L., Wang M., Putta S., Lanting L., Natarajan R., A microRNA circuit mediates transforming growth factor- Β 1 autoregulation in renal glomerular mesangial cells. Kidney International 2011 80 4 358 368 2-s2.0-80052248898 10.1038/ki.2011.43
53. Wang Q., Wang Y., Minto A. W., Wang J., Shi Q., Li X., Quigg R. J., MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. The FASEB Journal 2008 22 12 4126 4135 2-s2.0-57349186092 10.1096/fj.08-112326
54. Chung A. C., Dong Y., Yang W., Zhong X., Li R., Lan H. Y., Smad7 suppresses renal fibrosis via altering expression of TGF-beta/Smad3-regulated microRNAs. Molecular Therapy 2013 21 388 398 10.1038/mt.2012.251
55. Chung A. C. K., Huang X. R., Meng X., Lan H. Y., miR-192 mediates TGF- β /Smad3-driven renal fibrosis. Journal of the American Society of Nephrology 2010 21 8 1317 1325 2-s2.0-77955611511 10.1681/ASN.2010020134
56. Kato M., Putta S., Wang M., Yuan H., Lanting L., Nair I., Gunn A., Nakagawa Y., Shimano H., Todorov I., Rossi J. J., Natarajan R., TGF- β activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nature Cell Biology 2009 11 7 881 889 2-s2.0-67650085171 10.1038/ncb1897
57. Kato M., Wang L., Putta S., Wang M., Yuan H., Sun G., Lanting L., Todorov I., Rossi J. J., Natarajan R., Post-transcriptional up-regulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF- β -induced collagen expression in kidney cells. The Journal of Biological Chemistry 2010 285 44 34004 34015 2-s2.0-77958583070 10.1074/jbc.M110.165027
58. Deshpande S. D., Putta S., Wang M., Lai J. Y., Bitzer M., Nelson R. G., Lanting L. L., Kato M., Natarajan R., Transforming growth factor-beta induced cross talk between p53 and a microRNA in the pathogenesis of diabetic nephropathy. Diabetes 2013 62 9 3151 3162 10.2337/db13-0305
59. Putta S., Lanting L., Sun G., Lawson G., Kato M., Natarajan R., Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. Journal of the American Society of Nephrology 2012 23 3 458 469 2-s2.0-84857979740 10.1681/ASN.2011050485
60. Krupa A., Jenkins R., DongLuo D., Lewis A., Phillips A., Fraser D., Loss of microRNA-192 promotes fibrogenesis in diabetic nephropathy. Journal of the American Society of Nephrology 2010 21 3 438 447 2-s2.0-77949892330 10.1681/ASN.2009050530
61. Wang B., Herman-Edelstein M., Koh P., Burns W., Jandeleit-Dahm K., Watson A., Saleem M., Goodall G. J., Twigg S. M., Cooper M. E., Kantharidis P., E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor- β Diabetes 2010 59 7 1794 1802 2-s2.0-77954274715 10.2337/db09-1736
62. Zhong X., Chung A. C. K., Chen H.-Y., Meng X.-M., Lan H. Y., Smad3-mediated upregulation of miR-21 promotes renal fibrosis. Journal of the American Society of Nephrology 2011 22 9 1668 1681 2-s2.0-80052316668 10.1681/ASN.2010111168
63. Zhong X., Chung A., Chen H., Dong Y., Meng X., Li R., Yang W., Hou F., Lan H., miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. Diabetologia 2013 56 3 663 674 10.1007/s00125-012-2804-x
64. Dey N., Das F., Mariappan M. M., Mandal C. C., Ghosh-Choudhury N., Kasinath B. S., Choudhury G. G., MicroRNA-21 orchestrates high glucose-induced signals to TOR complex 1, resulting in renal cell pathology in diabetes. The Journal of Biological Chemistry 2011 286 29 25586 25603 2-s2.0-79960418116 10.1074/jbc.M110.208066
65. Wang J., Gao Y., Ma M., Li M., Zou D., Yang J., Zhu Z., Zhao X., Effect of miR-21 on renal fibrosis by regulating MMP-9 and TIMP1 in kk-ay diabetic nephropathy mice. Cell Biochemistry and Biophysics 2013 67 2 537 546 10.1007/s12013-013-9539-2
66. Fiorentino L., Cavalera M., Mavilio M., Conserva F., Menghini R., Gesualdo L., Federici M., Regulation of TIMP3 in diabetic nephropathy: a role for microRNAs. Acta Diabetologica 2013 50 6 965 969 10.1007/s00592-013-0492-8
67. Zhang Z., Peng H., Chen J., Chen X., Han F., Xu X., He X., Yan N., MicroRNA-21 protects from mesangial cell proliferation induced by diabetic nephropathy in db/db mice. FEBS Letters 2009 583 12 2009 2014 2-s2.0-67349089523 10.1016/j.febslet.2009.05.021
68. Meng X. M., Chung A. C., Lan H. Y., Role of the TGF-beta/BMP-7/Smad pathways in renal diseases. Clinical Science 2013 124 243 254
69. Lan H. Y., Chung A. C., TGF-beta/Smad signaling in kidney disease. Seminars in Nephrology 2012 32 3 236 243 10.1016/j.semnephrol.2012.04.002
70. Ding Q., Gladson C. L., Wu H., Hayasaka H., Olman M. A., Focal adhesion kinase (FAK)-related non-kinase inhibits myofibroblast differentiation through differential MAPK activation in a FAK-dependent manner. The Journal of Biological Chemistry 2008 283 40 26839 26849 2-s2.0-55249089456 10.1074/jbc.M803645200
71. Roy S., Khanna S., Hussain S.-R. A., Biswas S., Azad A., Rink C., Gnyawali S., Shilo S., Nuovo G. J., Sen C. K., MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovascular Research 2009 82 1 21 29 2-s2.0-62349141343 10.1093/cvr/cvp015
72. Thum T., Gross C., Fiedler J., Fischer T., Kissler S., Bussen M., Galuppo P., Just S., Rottbauer W., Frantz S., Castoldi M., Soutschek J., Koteliansky V., Rosenwald A., Basson M. A., Licht J. D., Pena J. T. R., Rouhanifard S. H., Muckenthaler M. U., Tuschl T., Martin G. R., Bauersachs J., Engelhardt S., MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008 456 7224 980 984 2-s2.0-57749168828 10.1038/nature07511
73. Kriegel A. J., Liu Y., Fang Y., Ding X., Liang M., The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury. Physiological Genomics 2012 44 4 237 244 2-s2.0-84857865756 10.1152/ physiolgenomics.00141.2011
74. Qin W., Chung A. C. K., Huang X. R., Meng X.-M., Hui D. S. C., Yu C.-M., Sung J. J. Y., Lan H. Y., TGF- β /Smad3 signaling promotes renal fibrosis by inhibiting miR-29. Journal of the American Society of Nephrology 2011 22 8 1462 1474 2-s2.0-79960946532 10.1681/ASN.2010121308
75. Van Rooij E., Sutherland L. B., Thatcher J. E., DiMaio J. M., Naseem R. H., Marshall W. S., Hill J. A., Olson E. N., Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proceedings of the National Academy of Sciences of the United States of America 2008 105 35 13027 13032 2-s2.0-51349141401 10.1073/pnas.0805038105
76. Xiao J., Meng X.-M., Huang X. R., Chung A. C., Feng Y.-L., Hui D. S., Yu C.-M., Sung J. J., Lan H. Y., miR-29 inhibits bleomycin-induced pulmonary fibrosis in mice. Molecular Therapy 2012 20 6 1251 1260 2-s2.0-84857675561 10.1038/mt.2012.36
77. Du B., Ma L.-M., Huang M.-B., Zhou H., Huang H.-L., Shao P., Chen Y.-Q., Qu L.-H., High glucose down-regulates miR-29a to increase collagen IV production in HK-2 cells. FEBS Letters 2010 584 4 811 816 2-s2.0-77649270362 10.1016/j.febslet.2009.12.053
78. Wang B., Komers R., Carew R., Winbanks C. E., Xu B., Herman-Edelstein M., Koh P., Thomas M., Jandeleit-Dahm K., Gregorevic P., Cooper M. E., Kantharidis P., Suppression of microRNA-29 expression by TGF- β 1 promotes collagen expression and renal fibrosis. Journal of the American Society of Nephrology 2012 23 2 252 265 2-s2.0-84856897634 10.1681/ASN.2011010055
79. Du T., Zamore P. D., microPrimer: the biogenesis and function of microRNA. Development 2005 132 21 4645 4652 2-s2.0-28044455435 10.1242/dev.02070 (Pubitemid 41685275)
80. Liu Y., Taylor N. E., Lu L., Usa K., Cowley A. W., Ferreri N. R., Yeo N. C., Liang M., Renal medullary microRNAs in dahl salt-sensitive rats: MiR-29b regulates several collagens and related genes. Hypertension 2010 55 4 974 982 2-s2.0-77950500403 10.1161/HYPERTENSIONAHA.109.144428
81. Ye Y., Hu Z., Lin Y., Zhang C., Perez-Polo J. R., Downregulation of microRNA-29 by antisense inhibitors and a PPAR- γ agonist protects against myocardial ischaemia-reperfusion injury. Cardiovascular Research 2010 87 3 535 544 2-s2.0-77954766181 10.1093/cvr/cvq053
82. Cushing L., Kuang P. P., Qian J., Shao F., Wu J., Little F., Thannickal V. J., Cardoso W. V., Lü J., miR-29 is a major regulator of genes associated with pulmonary fibrosis. American Journal of Respiratory Cell and Molecular Biology 2011 45 2 287 294 2-s2.0-80051655553 10.1165/rcmb.2010-0323OC
83. Howe E. N., Cochrane D. R., Richer J. K., The miR-200 and miR-221/222 microRNA families: opposing effects on epithelial identity. Journal of Mammary Gland Biology and Neoplasia 2012 17 1 65 77 2-s2.0-84858703841 10.1007/s10911-012-9244-6
84. Gregory P. A., Bert A. G., Paterson E. L., Barry S. C., Tsykin A., Farshid G., Vadas M. A., Khew-Goodall Y., Goodall G. J., The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nature Cell Biology 2008 10 5 593 601 2-s2.0-43049103824 10.1038/ncb1722 (Pubitemid 351627379)
85. Korpal M., Lee E. S., Hu G., Kang Y., The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. The Journal of Biological Chemistry 2008 283 22 14910 14914 2-s2.0-47249091921 10.1074/jbc.C800074200
86. Park S.-M., Gaur A. B., Lengyel E., Peter M. E., The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes and Development 2008 22 7 894 907 2-s2.0-41649091906 10.1101/gad.1640608 (Pubitemid 351482843)
87. Burk U., Schubert J., Wellner U., Schmalhofer O., Vincan E., Spaderna S., Brabletz T., A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Reports 2008 9 6 582 589 2-s2.0-44649163918 10.1038/embor.2008.74 (Pubitemid 351772923)
88. Wang B., Koh P., Winbanks C., Coughlan M. T., McClelland A., Watson A., Jandeleit-Dahm K., Burns W. C., Thomas M. C., Cooper M. E., Kantharidis P., miR-200a prevents renal fibrogenesis through repression of TGF- β 2 expression. Diabetes 2011 60 1 280 287 2-s2.0-78751516162 10.2337/db10-0892
89. Xiong M., Jiang L., Zhou Y., Qiu W., Fang L., Tan R., Wen P., Yang J., The miR-200 family regulates TGF- β 1-induced renal tubular epithelial to mesenchymal transition through smad pathway by targeting ZEB1 and ZEB2 expression. The American Journal of Physiology: Renal Physiology 2012 302 3 F369 F379 2-s2.0-84856184026 10.1152/ajprenal.00268.2011
90. Park J. T., Kato M., Yuan H., Castro N., Lanting L., Wang M., Natarajan R., FOG2 protein down-regulation by transforming growth factor-beta1-induced microRNA-200b/c leads to Akt kinase activation and glomerular mesangial hypertrophy related to diabetic nephropathy. The Journal of Biological Chemistry 2013 288 22469 22480 10.1074/jbc.M113.453043
91. Shi S., Yu L., Zhang T., Qi H., Xavier S., Ju W., Bottinger E., Smad2-dependent downregulation of miR-30 is required for TGF-beta-induced apoptosis in podocytes. PloS ONE 2013 8 e75572
92. Vogelmann S. U., Nelson W. J., Myers B. D., Lemley K. V., Urinary excretion of viable podocytes in health and renal disease. The American Journal of Physiology: Renal Physiology 2003 285 1 F40 F48 2-s2.0-0038045430 (Pubitemid 36818460)
93. Li D., Lu Z., Jia J., Zheng Z., Lin S., miR-124 is related to podocytic adhesive capacity damage in STZ-induced uninephrectomized diabetic rats. Kidney & Blood Pressure Research 2013 37 4-5 422 431 10.1159/000355721
94. Long J., Wang Y., Wang W., Chang B. H. J., Danesh F. R., Identification of microRNA-93 as a novel regulator of vascular endothelial growth factor in hyperglycemic conditions. The Journal of Biological Chemistry 2010 285 30 23457 23465 2-s2.0-77954941124 10.1074/jbc.M110.136168
95. Fu Y., Zhang Y., Wang Z., Wang L., Wei X., Zhang B., Wen Z., Fang H., Pang Q., Yi F., Regulation of NADPH oxidase activity is associated with miRNA-25-mediated NOX4 expression in experimental diabetic nephropathy. American Journal of Nephrology 2010 32 6 581 589 2-s2.0-78149352664 10.1159/000322105
96. Zhang Z., Luo X., Ding S., Chen J., Chen T., Chen X., Zha H., Yao L., He X., Peng H., MicroRNA-451 regulates p38 MAPK signaling by targeting of Ywhaz and suppresses the mesangial hypertrophy in early diabetic nephropathy. FEBS Letters 2012 586 1 20 26 2-s2.0-84655163918 10.1016/j.febslet.2011.07.042
97. Davis B. N., Hilyard A. C., Lagna G., Hata A., SMAD proteins control DROSHA-mediated microRNA maturation. Nature 2008 454 7200 56 61 2-s2.0-46449128469 10.1038/nature07086 (Pubitemid 351931982)
98. Li R., Chung A. C., Dong Y., Yang W., Zhong X., Lan H. Y., The microRNA miR-433 promotes renal fibrosis by amplifying the TGF-beta/Smad3-Azin1 pathway. Kidney International 2013 84 1129 1144
99. Zhou Q., Chung A. C., Huang X. R., Dong Y., Yu X., Lan H. Y., Identification of novel long noncoding RNAs associated with TGF-beta/Smad3- mediated renal inflammation and fibrosis by RNA sequencing. The American Journal of Pathology 2013 10.1016/j.ajpath.2013.10.007
100. Lan H. Y., Chung A. C. K., Transforming growth factor- β and smads. Contributions to Nephrology 2011 170 75 82 2-s2.0-79959187500 10.1159/000324949
101. Kato M., Zhang J., Wang M., Lanting L., Yuan H., Rossi J. J., Natarajan R., MicroRNA-192 in diabetic kidney glomeruli and its function in TGF- β -induced collagen expression via inhibition of E-box repressors. Proceedings of the National Academy of Sciences of the United States of America 2007 104 9 3432 3437 2-s2.0-33847682663 10.1073/pnas.0611192104 (Pubitemid 46364176)
102. Putta S., Lanting L., Sun G., Lawson G., Kato M., Natarajan R., Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. Journal of the American Society of Nephrology 2012 23 3 458 469 2-s2.0-84857979740 10.1681/ASN.2011050485
103. Mitchell P. S., Parkin R. K., Kroh E. M., Fritz B. R., Wyman S. K., Pogosova-Agadjanyan E. L., Peterson A., Noteboom J., O'Briant K. C., Allen A., Lin D. W., Urban N., Drescher C. W., Knudsen B. S., Stirewalt D. L., Gentleman R., Vessella R. L., Nelson P. S., Martin D. B., Tewari M., Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America 2008 105 30 10513 10518 2-s2.0-48749122914 10.1073/pnas.0804549105
104. Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., Guo J., Zhang Y., Chen J., Guo X., Li Q., Li X., Wang W., Zhang Y., Wang J., Jiang X., Xiang Y., Xu C., Zheng P., Zhang J., Li R., Zhang H., Shang X., Gong T., Ning G., Wang J., Zen K., Zhang J., Zhang C.-Y., Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Research 2008 18 10 997 1006 2-s2.0-53349177819 10.1038/cr.2008.282
105. Volinia S., Visone R., Galasso M., Rossi E., Croce C. M., Identification of microRNA activity by targets' reverse eXpression. Bioinformatics 2010 26 1 91 97 2-s2.0-77449136113
106. Zampetaki A., Willeit P., Drozdov I., Kiechl S., Mayr M., Profiling of circulating microRNAs: from single biomarkers to re-wired networks. Cardiovascular Research 2012 93 4 555 562 2-s2.0-84857930607 10.1093/cvr/cvr266
107. Argyropoulos C., Wang K., McClarty S., Huang D., Bernardo J., Ellis D., Orchard T., Galas D., Johnson J., Urinary MicroRNA profiling in the nephropathy of type 1 diabetes. PLoS ONE 2013 8 e54662
108. Barutta F., Tricarico M., Corbelli A., Annaratone L., Pinach S., Grimaldi S., Bruno G., Cimino D., Taverna D., Deregibus M. C., Rastaldi M. P., Perin P. C., Gruden G., Urinary exosomal microRNAs in incipient diabetic nephropathy. PloS ONE 2013 8 e73798
109. Chen K., Rajewsky N., Natural selection on human microRNA binding sites inferred from SNP data. Nature Genetics 2006 38 12 1452 1456 2-s2.0-33751520430 10.1038/ng1910 (Pubitemid 44837570)
110. Saunders M. A., Liang H., Li W.-H., Human polymorphism at microRNAs and microRNA target sites. Proceedings of the National Academy of Sciences of the United States of America 2007 104 9 3300 3305 2-s2.0-33847665108 10.1073/pnas.0611347104 (Pubitemid 46364154)
111. Zhou J., Peng R., Li T., Luo X., Peng H., Zha H., Yin P., Wen L., Zhang Z., A potentially functional polymorphism in the regulatory region of let-7a-2 is associated with an increased risk for diabetic nephropathy. Gene 2013 527 2 456 461 10.1016/j.gene.2013.06.088